Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line

Adult Aged Amoxicillin / administration & dosage Anti-Bacterial Agents / administration & dosage Clarithromycin / administration & dosage Drug Administration Schedule Drug Therapy, Combination Female Helicobacter Infections / drug therapy Helicobacter pylori Humans Male Middle Aged Pyrroles / administration & dosage Sulfonamides / administration & dosage
antibiotics - clinical trials clinical trials gastric inflammation helicobacter pylori - treatment

Journal

Gut
ISSN: 1468-3288
Titre abrégé: Gut
Pays: England
ID NLM: 2985108R

Informations de publication

Date de publication:
06 2020
Historique:
received: 27 09 2019
revised: 04 12 2019
accepted: 25 12 2019
pubmed: 10 1 2020
medline: 17 2 2021
entrez: 10 1 2020
Statut: ppublish

Résumé

To date, no randomised trials have compared the efficacy of vonoprazan and amoxicillin dual therapy with other standard regimens for This prospective, randomised clinical trial was performed at seven Japanese institutions. Patients with Between October 2018 and June 2019, 629 subjects were screened and 335 were randomised. The eradication rates of VA-dual and VAC-triple therapies were 84.5% and 89.2% (p=0.203) by intention-to-treat analysis, respectively, and 87.1% and 90.2% (p=0.372) by per-protocol analysis, respectively. VA-dual was non-inferior to VAC-triple in the per-protocol analysis. The eradication rates in strains resistant to clarithromycin for VA-dual were significantly higher than those for VAC-triple (92.3% vs 76.2%; p=0.048). The incidence of adverse events was equal between groups. The 7-day vonoprazan and low-dose amoxicillin dual therapy provided acceptable UMIN000034140.

Identifiants

DOI: 10.1136/gutjnl-2019-319954 PMID: 31915235 PMC: PMC7282559
pubmed: 31915235
pii: gutjnl-2019-319954
doi: 10.1136/gutjnl-2019-319954
pmc: PMC7282559
doi:

Substances chimiques

1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamine 0
Anti-Bacterial Agents 0
Pyrroles 0
Sulfonamides 0
Amoxicillin 804826J2HU
Clarithromycin H1250JIK0A

Banques de données

JPRN
['UMIN000034140']

Types de publication

Comparative Study Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1019-1026

Commentaires et corrections

Type : CommentIn

Informations de copyright

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: TG received honorarium from Takeda Pharmaceutical Company Limited, the manufacturer of study drugs.

Références

Gastroenterology. 2016 Jul;151(1):51-69.e14
pubmed: 27102658
Helicobacter. 2017 Jun;22(3):
pubmed: 28125857
Am J Gastroenterol. 2017 Feb;112(2):212-239
pubmed: 28071659
Aliment Pharmacol Ther. 1997 Oct;11(5):919-27
pubmed: 9354201
Aliment Pharmacol Ther. 2015 Apr;41(7):636-48
pubmed: 25707624
J Gastroenterol. 2018 Jun;53(6):718-724
pubmed: 29110085
J Gastroenterol Hepatol. 1998 Mar;13(3):301-4
pubmed: 9570244
Am J Gastroenterol. 1998 Apr;93(4):584-90
pubmed: 9576452
Gut. 2016 Sep;65(9):1439-46
pubmed: 26935876
Helicobacter. 2017 Dec;22(6):
pubmed: 28833925
Aliment Pharmacol Ther. 2015 Sep;42(6):719-30
pubmed: 26193978
Gastroenterology. 2018 Nov;155(5):1372-1382.e17
pubmed: 29990487
Helicobacter. 2019 Aug;24(4):e12596
pubmed: 31111580
Am J Gastroenterol. 2016 Dec;111(12):1736-1742
pubmed: 27670603
Helicobacter. 2016 Sep;21 Suppl 1:3-7
pubmed: 27531531
Helicobacter. 2019 Oct;24(5):e12646
pubmed: 31368629
Gut. 2013 Jan;62(1):34-42
pubmed: 22580412
Helicobacter. 2018 Sep;23 Suppl 1:e12514
pubmed: 30203587
Stat Med. 2003 Jan 30;22(2):169-86
pubmed: 12520555
Gastric Cancer. 2019 May;22(3):435-445
pubmed: 30206731
Helicobacter. 2018 Apr;23(2):e12466
pubmed: 29369454
Helicobacter. 2017 Sep;22 Suppl 1:
pubmed: 28891136
Lancet. 2016 Nov 12;388(10058):2355-2365
pubmed: 27769562
Am J Gastroenterol. 2019 Mar;114(3):437-445
pubmed: 30807294
Adv Ther. 2016 Sep;33(9):1519-35
pubmed: 27432383
Eur J Gastroenterol Hepatol. 2018 Jun;30(6):621-625
pubmed: 29481383
Aliment Pharmacol Ther. 2000 Feb;14(2):217-24
pubmed: 10651663
Gut. 2017 Jan;66(1):6-30
pubmed: 27707777
Am J Gastroenterol. 2019 Jun;114(6):900-906
pubmed: 31095531
Clin Gastroenterol Hepatol. 2015 May;13(5):895-905.e5
pubmed: 25460556
Gut. 2014 Feb;63(2):244-9
pubmed: 23665990
Aliment Pharmacol Ther. 2015 Mar;41(6):581-9
pubmed: 25776067
Helicobacter. 2018 Feb;23(1):
pubmed: 29178562
Lancet Infect Dis. 2018 Mar;18(3):318-327
pubmed: 29276051
Gut. 2018 Dec;67(12):2092-2096
pubmed: 29382776
Lancet. 2011 Mar 12;377(9769):905-13
pubmed: 21345487
Helicobacter. 2016 Feb;21(1):29-34
pubmed: 25982426
Digestion. 2019 Aug 21;:1-9
pubmed: 31434101
Am J Gastroenterol. 2016 Jul;111(7):949-56
pubmed: 27185079
J Med Microbiol. 1996 Jun;44(6):425-33
pubmed: 8636959
World J Gastroenterol. 2017 Apr 28;23(16):2854-2869
pubmed: 28522904
Gut Liver. 2019 Sep 15;13(5):531-540
pubmed: 31505907
Gut. 2015 Nov;64(11):1715-20
pubmed: 26338726

Auteurs

Sho Suzuki (S)

Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan.
Department of Gastroenterology, Yuri Kumiai General Hospital, Yurihonjo, Akita, Japan.
ORCID: 0000-0003-4831-1409

Takuji Gotoda (T)

Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan takujigotoda@yahoo.co.jp.
ORCID: 0000-0001-6904-6777

Chika Kusano (C)

Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan.

Hisatomo Ikehara (H)

Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan.

Ryoji Ichijima (R)

Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan.

Motoki Ohyauchi (M)

Department of Gastroenterology, Osaki Citizen Hospital, Osaki, Miyagi, Japan.

Hirotaka Ito (H)

Department of Gastroenterology, Osaki Citizen Hospital, Osaki, Miyagi, Japan.

Masashi Kawamura (M)

Department of Gastroenterology, Sendai City Hospital, Sendai, Miyagi, Japan.

Yohei Ogata (Y)

Department of Gastroenterology, Sendai City Hospital, Sendai, Miyagi, Japan.

Masahiko Ohtaka (M)

Yamanashi Koseiren Health Care Center, Kofu, Yamanashi, Japan.

Moriyasu Nakahara (M)

Department of Gastroenterology, Chichibu Municipal Hospital, Chichibu, Saitama, Japan.

Koichi Kawabe (K)

Department of Gastroenterology, Fukaya Red Cross Hospital, Fukaya, Saitama, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

Recherchemedicale.com › Personnes › Tranches d'âge › Adulte › Seven-day vonoprazan and low-dose amoxicillin...
Recherchemedicale.com › Personnes › Tranches d'âge › Adulte › Sujet âgé › Seven-day vonoprazan and low-dose amoxicillin...
Recherchemedicale.com › Composés hétérocycliques › Composés hétérocycliques à cycles fusionnés › Composés hétérobicycliques › bêta-Lactames › Pénicillines › Benzylpénicilline › Ampicilline › Amoxicilline › Seven-day vonoprazan and low-dose amoxicillin...
Recherchemedicale.com › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Anti-infectieux › Antibactériens › Seven-day vonoprazan and low-dose amoxicillin...
Recherchemedicale.com › Composés chimiques organiques › Lactones › Érythromycine › Clarithromycine › Seven-day vonoprazan and low-dose amoxicillin...
Recherchemedicale.com › Thérapeutique › Traitement médicamenteux › Calendrier d'administration des médicaments › Seven-day vonoprazan and low-dose amoxicillin...
Recherchemedicale.com › Thérapeutique › Traitement médicamenteux › Association de médicaments › Seven-day vonoprazan and low-dose amoxicillin...
Recherchemedicale.com › Infection › Infections bactériennes et mycoses › Infections bactériennes › Infections bactériennes à Gram négatif › Infections à Helicobacter › Seven-day vonoprazan and low-dose amoxicillin...
Recherchemedicale.com › Bactéries › Proteobacteria › Epsilonproteobacteria › Campylobacterales › Helicobacteraceae › Helicobacter › Helicobacter pylori › Seven-day vonoprazan and low-dose amoxicillin...
Recherchemedicale.com › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Seven-day vonoprazan and low-dose amoxicillin...
Recherchemedicale.com › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › Seven-day vonoprazan and low-dose amoxicillin...
Recherchemedicale.com › Composés hétérocycliques › Composés hétéromonocycliques › Azoles › Pyrroles › Seven-day vonoprazan and low-dose amoxicillin...
Recherchemedicale.com › Composés chimiques organiques › Composés du soufre › Sulfones › Sulfonamides › Seven-day vonoprazan and low-dose amoxicillin...